Drug Profile
Research programme : anti-BTLA monoclonal antibodies - Merck & Co
Alternative Names: 40E4; 40E4 mIgG1; D265ALatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Monoclonal antibodies
- Mechanism of Action B-cell antigen receptor agonists; T-lymphocyte differentiation antigen antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Apr 2017 Preclinical trials in Cancer in USA (unspecified route)
- 01 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 108th Annual meeting of the American Association for Cancer Research (AACR-2017)